20MO Time to deterioration in quality of life in patients (pts) with advanced endometrial cancer (aEC) treated with lenvatinib plus pembrolizumab (L+P) or treatment of physician’s choice (TPC)
Titel:
20MO Time to deterioration in quality of life in patients (pts) with advanced endometrial cancer (aEC) treated with lenvatinib plus pembrolizumab (L+P) or treatment of physician’s choice (TPC)
Auteur:
Lorusso, D. Colombo, N. Casado Herraez, A. Santin, A.D. Colomba, E. Miller, D.S. Fujiwara, K. Pignata, S. Baron-Hay, S.E. Ray-Coquard, I.L. Shapira-Frommer, R. Kim, Y.M. McCormack, M. Massaad, R. Martin Nguyen, A. Zhao, Q. McKenzie, J. Prabhu, V.S. Makker, V.